January 4, 2023 -- Hookipa Pharma, the developer of a new class of immunotherapies using an arenavirus platform, on Wednesday announced that it has been granted a $5 million milestone payment under a collaboration agreement with Gilead Sciences.
Hookipa said it completed and delivered a regulatory support package for Gilead's Phase 1 clinical trial of an investigational therapeutic vaccine for chronic hepatitis B using the developer's arenaviral platform.
The first participant in the Phase 1 clinical trial is expected to be dosed in 2023.
"Chronic hepatitis B infection remains an area of considerable unmet need, and we look forward to seeing the potential impact of our novel arenaviral platform as a component of care," Joern Aldag, CEO of Hookipa, said in a statement.
Preclinical data on the hepatitis B vaccine as a potential component for a curative regimen were recently presented at the American Association for the Study of Liver Diseases (AASLD).
Gilead is solely responsible for further development and commercialization of the hepatitis B product candidate.
Hookipa noted that it is eligible to receive milestone payments based on the achievement of specified development, regulatory, and commercial milestones up to a total of more than $190 million, and it is also eligible to receive tiered royalties on net sales.
Copyright © 2023 scienceboard.net